Feasibility and adherence to moderate intensity cardiovascular fitness training following stroke: a pilot randomized controlled trial

Table 4 Pre and post data, mean (SD) unless otherwise specified

	Baseline Intervention (n = 10)	Follow-up intervention	MD (95% CI) (n = 10^a)	P	Baseline control (n = 10)	Follow-up control	MD (95% CI) (n = 9)	P
VO₂ peak	17.5 (2.9)	20.1 (4.9)	2.6 (0.5, 4.6)	0.02*	14.4 (3.7)	17.4 (4.4)	3.0 (1.0, 5.0)	0.01*
6MWT	400.9 (111.6)	443.4 (126.4)	42.5 (−10.9, 95.9)	0.11	344.8 (150.6)	370.9 (126.0)	26.1 (−15.3, 67.5)	0.18
10MWT Self	1.16 (0.29)	1.20 (0.21)	0.04 (−0.11, 0.20)	0.53	0.95 (0.38)	0.97 (0.36)	0.02 (−0.13, 0.17)	0.74
10MWT Fast	1.47 (0.36)	1.57 (0.41)	0.10 (−0.13, 0.32)	0.35	1.20 (0.47)	1.31 (0.52)	0.10 (−0.04, 0.25)	0.13
SF-36 PCS^b	43.12 (8.65)	45.78 (8.97)	2.67 (−2.7, 8.0)	0.28	37.92 (10.16)	40.43 (9.90)	2.51 (−6.1, 11.1)	0.52
SF-36 MCS^b	42.63 (14.72)	48.48 (17.65)	5.85 (−1.9, 13.6)	0.12	34.68 (20.35)	46.19 (10.50)	11.51 (0.09, 22.9)	0.049*
PHQ-9	7.0 (7.1)	4.2 (7.1)	−2.8 (−8.1, 2.5)	0.26	8.1 (6.2)	3.8 (3.6)	−4.3 (−6.6, −2.0)	0.003*

CI Confidence interval. p values are calculated using paired samples t-tests with the exception of the 10MWT analyses which were performed using the Wilcoxon-signed ranks test. VO₂ = ml/kg/min; 6MWT Six minute walk test (metres), 10MWT 10 m walk test, SF-36 Short Form 36, PCS Physical Component Summary Score, MCS Mental Component Summary Score, PHQ-9 Patient Health Questionnaire
One participant in the control group was lost to follow-up
*p < 0.05. ^aExcept for VO₂ peak where n = 9. ^bn = 8 (Intervention), n = 9 (Control)

ISSN: 1471-2377